Clinical Trial Update: A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety of combining ibrutinib with rituximab and CHOP chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• IMBRUVICA (IBRUTINIB)
• Oncovin (vincristine)
• PREDNISONE (Prednisone)
• Rituxan (rituximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: CD20-positive B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED